Joshua Brody, MD, PhD, of Mount Sinai Hospital, gives an overview of a clinical trial by Dana Farber that shows patients with primary central nervous system lymphoma has a 100% response rate with anti-PD1 therapy at the 58th ASH Annual Meeting in San Diego, CA.
100% Response Rate with Anti-PD1 Therapy for Patients with Lymphoma
